Home Featured Page 196

Featured

Latest

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of...

Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants...

PT277 – Ryan Zurrer – Venture Capital, Reciprocity, and the Regenerative...

MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

MAPS and Wesana Health Resume Negotiations

Field Trip Launches Site Management Organization (SMO) Services, Hires Stéphan Côté...

MindMed Appoints Robert Barrow as Chief Executive Officer and Director

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial...

HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S....

atai Life Sciences Has Been Selected for Addition to the NASDAQ...

1...195196197...300 Page 196 of 300

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants...

Q3’25 Psychedelic Lobbying Update

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

The Psychedelic News Feed: October 20 – 26, 2025

Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of...

Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants...

PT277 – Ryan Zurrer – Venture Capital, Reciprocity, and the Regenerative...

MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

MAPS and Wesana Health Resume Negotiations

Field Trip Launches Site Management Organization (SMO) Services, Hires Stéphan Côté...

MindMed Appoints Robert Barrow as Chief Executive Officer and Director

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial...

HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S....

atai Life Sciences Has Been Selected for Addition to the NASDAQ...

EDITOR PICKS

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants...

Q3’25 Psychedelic Lobbying Update

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY